In light of RxPonder results for postmenopausal women with early stage node positive HR+HER2- breast cancer, when is there a role for full axillary LN dissection to confirm degree of nodal involvement and when would sentinel LN evaluation be sufficient?
How would this affect adjuvant radiation plan in breast conservation therapy patients and mastectomy patients?
1 Answer
Mednet Member
Medical Oncology · Northwestern Medicine Cancer Center at KishHealth
Answered on
I don’t think the RxPonder study changes surgical management. Still follow Z0011 paradigm.
Join for free or sign in to see the full answer